Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - rivaroxabanum - rivaroxaban-mepha vascular 2.5 mg filmtabletten - rivaroxabanum 2.5 mg, natrii laurilsulfas, lactosum monohydricum 184.7 mg, hypromellosum, carmellosum natricum conexum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (flavum), pro compresso obducto corresp. natrium max. 1.19 mg. - in combinazione con acido acetilsalicilico per la prevenzione di gravi atherothrombotischer eventi nei pazienti con malattia coronarica o franca periferico arterioso gefässerkrankung e un elevato rischio di eventi ischemici - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenti antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

doc generici srl - rivaroxaban - rivaroxaban

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agenti antitrombotici - prevenzione del tromboembolismo venoso (tev) in pazienti adulti sottoposti a chirurgia sostitutiva elettiva dell'anca o del ginocchio. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 per haemodynamically instabile pe pazienti). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 e 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

zentiva italia s.r.l. - rivaroxaban - rivaroxaban

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

vi.rel pharma s.r.l - rivaroxaban - rivaroxaban

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

zaklady farmaceutyczne polpharma sa - rivaroxaban - rivaroxaban

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

teva italia s.r.l. - rivaroxaban - rivaroxaban

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - rivaroxaban - rivaroxaban

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - rivaroxabanum - compresse rivestite con film - rivaroxabanum 10 mg, natrii laurilsulfas, lactosum monohydricum 177.2 mg, hypromellosum, carmellosum natricum conexum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 120, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium max. 1.19 mg. - thromboseprophylaxe e trattamento di ictus e embolieprophylaxe, trattamento dell'embolia polmonare (le) - synthetika